UCL study to assess link between navigation and AD using virtual reality
The progressive neurodegenerative condition is the most common form of dementia
Read Moreby Jen Brogan | Apr 24, 2024 | News | 0
The progressive neurodegenerative condition is the most common form of dementia
Read Moreby Jen Brogan | Apr 3, 2024 | News | 0
The progressive neurodegenerative disease is estimated to affect 24 million people globally
Read Moreby Jen Brogan | Mar 14, 2024 | News | 0
Affecting 55 million people globally, dementia impairs the ability to remember, think or make decisions
Read Moreby Jen Brogan | Mar 4, 2024 | News | 0
Around 900,000 people in the UK are affected by the progressive neurodegenerative disease
Read Moreby Jen Brogan | Feb 16, 2024 | News | 0
NRTX-1001 is being assessed for drug-resistant mesial temporal lobe epilepsy
Read Moreby Jen Brogan | Jan 4, 2024 | News | 0
High amounts of disrupted sleep were found to affect memory and thinking performance
Read Moreby Jen Brogan | Dec 18, 2023 | News | 0
MCI patients had 25% lower levels of serotonin compared to healthy patients
Read Moreby Jen Brogan | Dec 14, 2023 | News | 0
The collaboration aims to develop biomarker-based diagnostics for the condition
Read Moreby Jen Brogan | Nov 24, 2023 | News | 0
The findings could benefit patients living with neurodegenerative conditions
Read Moreby Jen Brogan | Nov 22, 2023 | News | 0
The trial will use an AI screening platform to identify those most at risk of dementia
Read Moreby Jen Brogan | Oct 20, 2023 | News | 0
The new technology was safely trialled on 20 healthy volunteers for the first time ever
Read Moreby Jen Brogan | Oct 12, 2023 | News | 0
The financing will support the biotech’s clinical study of people with AD as a lead programme
Read MorePharmaTimes Media Ltd.
Mansard House
Church Road
Little Bookham
Leatherhead
Surrey KT23 3JG
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
F: +44 (0)20 7240 4479